Research programme: cellular therapeutics - Vycellix

Drug Profile

Research programme: cellular therapeutics - Vycellix

Alternative Names: VY OZ; VY X - Vycellix; VY-X

Latest Information Update: 10 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vycellix
  • Class Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Viral infections

Most Recent Events

  • 28 Feb 2017 Vycellix enters into a collaborative research arrangement with Moffitt Cancer for adoptive cell immunotherapies including VY OZ and VY
  • 02 May 2016 Preclinical trials in Cancer in USA (Parenteral)
  • 02 May 2016 Preclinical trials in Viral infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top